An additional study on a classical protein kinase C inhibitor, revealed high potency against the mutated EGFR and significantly reduced tumor growth in an in vivo xenograft model employing an EGFR-mutant NSCLC cell line containing the EGFR c.2369C>T (T790M) mutation (27). This evidence concerns the gene EGFR and neoplasm.